DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
Steroid therapy is the first-line treatment for graft-versus-host disease (GVHD). If GVHD does not respond to initial therapies, doctors may consider chemotherapy, monoclonal antibodies ...
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...
The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback